Heart and Vessels

, Volume 10, Issue 1, pp 46–53 | Cite as

Centrifugal and roller pumps — are there differences in coagulation and fibrinolysis during and after cardiopulmonary bypass?

  • Bernhard E. Steinbrueckner
  • Udo Steigerwald
  • Franz Keller
  • Konrad Neukam
  • Olaf Elert
  • Joerg Babin-Ebell


A number of hemostatic parameters reflecting the activation of coagulation and fibrinolysis were investigated in a prospective study of 24 patients undergoing cardiopulmonary bypass (CPB) during heart surgery. The patients were randomized to a group in which either a roller (group 1) or a centrifugal pump (group 2) was used. Blood samples were taken preoperatively, at the onset of and every 20min during CPB, after the administration of protamine, and 4, 20, 44, and 68 h postoperatively. The groups did not differ significantly in hematocrit, fibrinogen, factor XIII, and antithrombin III. Significant differences in favor of group 2 during and after CPB were found in prothrombin fragment F1+2, plasmin-antiplasmin complex (PAP), thrombin-antithrombin complex (TAT), and D-dimer (F1+2P < 0.01 after 80-min CPB, PAPP < 0.005 after 40-min CPB, TAT and D-dimerP < 0.05 after 100-min CPB, D-dimer and PAPP < 0.05 after protamine administration, TAT and F1+2 4h after CPB).

These findings indicate the activation of fibrinolysis preceding thrombin generation during cardiopulmonary bypass. In addition, we conclude that centrifugal blood pumping is beneficial in avoiding excessive activation of both coagulation and fibrinolysis.

Key words

Extracorporeal circulation Centrifugal pump Coagulation Fibrinolysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE (1992) Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. J Thorac Cardiovasc Surg 104:642–647Google Scholar
  2. 2.
    Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA (1988) Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 59:62–67Google Scholar
  3. 3.
    Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U (1990) Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 14:46–48Google Scholar
  4. 4.
    Mammen EF, Koets MH, Washington BC, Wolk LM, Brown JM, Burdick M, Selik NR, Wilson RF (1985) Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 11:281–292Google Scholar
  5. 5.
    Brister SJ, Ofosu FA, Buchanan MR (1993) Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant? Thromb Haemost 70:259–262Google Scholar
  6. 6.
    Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D (1986) Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol 23:223–229Google Scholar
  7. 7.
    Nishida H, Yamaki F, Nakatani H, Endo M, Koyanagi H, Oshiyama H, Horiuchi K, Kijima T, Nojiri C, Fukasawa H, et al. (1993) Development of the Terumo Capiox centrifugal pump and its clinical application to open heart surgery: A comparative study with the roller pump. Artif Organs 17:323–327Google Scholar
  8. 8.
    Berki T, Guerbuez A, Isik O, Akkaya H, Bayezid O, Yakut C (1992) Cardiopulmonary bypass using centrifugal pump. Vasc Surg 26:123–134Google Scholar
  9. 9.
    Wheeldon DR, Bethune DW, Gill RD (1990) Vortex pumping for routine cardiac surgery: A comparative study. Perfusion 5:135–143Google Scholar
  10. 10.
    Horton AM, Butt W (1992) Pump-induced haemolysis: Is the constrained vortex pump better or worse than the roller pump? Perfusion 7:103–108Google Scholar
  11. 11.
    Jakob H, Hafner G, Iversen S, Hake U, Thelemann C, Prellwitz W, Oelert H (1992) Reoperation and the centrifugal pump? Eur J Cardiothorac Surg 6:59–63Google Scholar
  12. 12.
    Marciniak E, Gockerman JP (1977) Heparin-induced decrease in circulating antithrombin III. Lancet 2:581–584Google Scholar
  13. 13.
    Bick RL, Arbegast N, Crawford L, Holtermann M, Adams T, Schmalhorst W (1975) Hemostatic defects induced by cardiopulmonary bypass. Vasc Surg 9:228–243Google Scholar
  14. 14.
    Ekert H, Montgomery D, Aberdeen E (1971) Fibrinolysis during extracorporeal circulation: Comparison of the effects of disc and membrane oxygenators. Circ Res 28:512–517Google Scholar
  15. 15.
    Tanaka K, Morimoto T, Yada I, Kusagawa M, Deguchi K (1987) Physiologic role of enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery. Trans Am Soc Artif Intern Organs 33:505–509Google Scholar
  16. 16.
    Kisiel W (1979) Human plasma protein C: Isolation, characterization and mechanism of activation by alpha thrombin. J Clin Invest 64:761–769Google Scholar
  17. 17.
    Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ (1985) Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 82:1121–1125Google Scholar
  18. 18.
    Ichinose A, Fujikawa K, Suyama T (1986) The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261:3486–3489Google Scholar
  19. 19.
    Gurewich V, Pannell R, Louie S (1984) Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). J Clin Invest 73:1731Google Scholar
  20. 20.
    Fritz H, Wunderer G (1983) Biochemistry and application of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimforsch Drug Res 33:479–494Google Scholar
  21. 21.
    de Smet A, Joen M, van Oeveren W, Roozendaal K, Harder M, Ejisman L, Wildevuur C (1990) Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 100:520–527Google Scholar
  22. 22.
    Stibbe J, Kluft C, Brommer EJP, Golmes M, de Jong DS, Nauta J (1984) Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue type) plasminogen activator. Eur J Clin Invest 14:375–382Google Scholar
  23. 23.
    Kitaguchi H, Hijikata A, Hirata M (1979) Effect of thrombin on plasminogen activator release from isolated perfused dog leg. Thromb Res 16:407–420Google Scholar
  24. 24.
    Cash JD (1979) Control mechanisms of activator release. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC (eds) Progress in chemical fibrinolysis and thrombolysis. Raven, New York, pp 65–75Google Scholar
  25. 25.
    Tappy L, Hauert J, Bachmann F (1984) Effects of hypoxia and acidosis on vascular plasminogen activator release in the pig ear perfusion system. Thromb Res 33:117–124Google Scholar
  26. 26.
    Plow E (1982) Leukocyte elastase release during blood coagulation: A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 69:564Google Scholar
  27. 27.
    Dapper F, Neppl H, Wozniak G, Strube I, Zickmann B, Heherlein FW, Neuhof H (1992) Effects of pulsatile and nonpulsatile perfusion mode during extracorporeal circulation — a comparative clinical study. Thorac Cardiovasc Surg 40:345–351Google Scholar
  28. 28.
    Brunner G, Simon MM, Kramer MD (1990) Activation of pro-urokinase by the human T-cell-associated serin proteinase HuTSP1. FEBS Lett 260:141–144Google Scholar
  29. 29.
    Jakob H, Kutschera Y, Palzer B, Prellwitz W, Oelert H (1990) In vitro assessment of centrifugal pumps for ventricular assist. Artif Organs 14:278–283Google Scholar
  30. 30.
    Parault BG, Conrad SA (1991) The effect of extracorporeal circulation time and patient age on platelet retention during cardiopulmonary bypass: A comparison of roller and centrifugal pumps. J Extracorporeal Tech 23:34–38Google Scholar
  31. 31.
    Van der Poll T, Bueller HR, Ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, Ten Cate JW (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622–1627Google Scholar
  32. 32.
    Bevilacqua MP, Pober JS, Majeu GR, Cotran RS, Gimbrone MA (1984) Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160:618Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Bernhard E. Steinbrueckner
    • 1
  • Udo Steigerwald
    • 1
  • Franz Keller
    • 1
  • Konrad Neukam
    • 2
  • Olaf Elert
    • 2
  • Joerg Babin-Ebell
    • 2
  1. 1.Central Laboratory of the University Medical CentreUniversity HospitalWuerzburgGermany
  2. 2.Clinic of Cardiothoracic SurgeryUniversity HospitalWuerzburgGermany

Personalised recommendations